Drug Trial Radar · NCT06931691
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jun 10, 2025
Primary completion
Apr 21, 2027
Study completion Apr 21, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 17, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The implementation of new standards for the management of PNH and the use of iptacopan in patients with PNH are expected to change the treatment landscape and improve the overall prognosis of patients. Based on these backgrounds, we plan to conduct a real-world study of iptacopan to further evaluate its impact on treatment-related outcomes, disease management, and healthcare resource utilization in Chinese patients with PNH.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
LNP023Drug
Capsules for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in hemoglobin (Hb) levels at designated time pointsTime frame: Baseline, 12 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Jinan, China · Recruiting
Novartis Investigative Site
Tianjin, China · Recruiting
Novartis Investigative Site
Tianjin, China · Recruiting
Novartis Investigative Site
Wuhan, China · Recruiting
Novartis Investigative Site
Hefei, Anhui, China · Recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China · Recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China · Recruiting
Novartis Investigative Site
Shijiazhuang, Hebei, China · Recruiting
Novartis Investigative Site
Zhengzhou, Henan, China · Recruiting
Novartis Investigative Site
Zhengzhou, Henan, China · Recruiting
Novartis Investigative Site
Wuhan, Hubei, China · Recruiting
Novartis Investigative Site
Nantong, Jiangsu, China · Recruiting
Novartis Investigative Site
Nanchang, Jiangxi, China · Recruiting
Novartis Investigative Site
Changchun, Jilin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.